Cyteir Therapeutics to Participate in the 2022 Bank of America Healthcare Conference

Rhea-AI Summary

Cyteir Therapeutics (NASDAQ: CYT) will have key leaders, Andrew Gengos and Judd Englert, present at the 2022 Bank of America Healthcare Conference in Las Vegas on May 11, 2022, at 4:20 p.m. ET. A live webcast of the discussion will be accessible via the Cyteir website and available for replay for 30 days post-event. Cyteir is focused on developing next-generation synthetically lethal therapies for cancer, with their lead compound, CYT-0851, currently in a Phase 1/2 clinical trial for various tumors.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that Andrew Gengos, Chief Business Officer and Judd Englert, MD, PhD, Senior Vice President Clinical Research & Development will participate in a fireside chat at the 2022 Bank of America Healthcare Conference. The meeting is being held in person in Las Vegas on Wednesday, May 11, 2022 at 4:20 p.m. ET (1:20 p.m. PT).

A live webcast of the presentation will be available in the Investors & Media section of the Cyteir website at www.cyteir.com. A webcast replay will also be available on the website shortly after conclusion of the event for 30 days.

About Cyteir Therapeutics, Inc.

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. At Cyteir, we employ an integrated target discovery approach that incorporates a critical evaluation of the target biology with internal and external information from a variety of genetic and chemical synthetic lethality screens to fuel our drug discovery and development pipeline. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors. Follow Cyteir on social media: LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005174/en/

INVESTOR CONTACT:

Lisa Hayes

Vice President, Investor Relations and Corporate Communications

908-868-8926

Lisa.Hayes@cyteir.com



MEDIA CONTACT:

Michele Parisi

925-429-1850

mparisi@forwardhealthinc.com

Source: Cyteir Therapeutics

FAQ

What is the date and time of Cyteir Therapeutics' presentation at the Bank of America Healthcare Conference?

Cyteir Therapeutics will present on May 11, 2022, at 4:20 p.m. ET.

Who from Cyteir Therapeutics will participate in the Bank of America Healthcare Conference?

Andrew Gengos and Judd Englert will represent Cyteir Therapeutics at the conference.

How can I watch the presentation of Cyteir Therapeutics at the conference?

The presentation will be available via a live webcast on the Cyteir website.

What is the main focus of Cyteir Therapeutics?

Cyteir Therapeutics focuses on discovering and developing next-generation synthetically lethal therapies for cancer.

What clinical trial is Cyteir currently conducting?

Cyteir is conducting a Phase 1/2 clinical trial for its lead compound, CYT-0851, targeting hematologic and solid tumors.